Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

641. Paliperidone palmitate - Schizophrenia

Paliperidone palmitate - Schizophrenia Common Drug Review CEDAC Meeting – November 17, 2010; CEDAC Meeting – January 19, 2011; CEDAC Meeting – March 23, 2011 Notice of CEDAC Final Recommendation – April 25, 2011 © 2011 CADTH Page 1 of 6 CEDAC FINAL RECOMMENDATION PALIPERIDONE PALMITATE (Invega Sustenna – Janssen Inc.) Indication: Schizophrenia Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that paliperidone palmitate not be listed at the resubmitted price. Reason (...) Canada for the treatment of schizophrenia. After two initial intramuscular (deltoid) injections (150 mg on day one and 100 mg on day eight), paliperidone (as palmitate) is administered through either deltoid or gluteal intramuscular injection monthly, at a recommended maintenance dose of 75 mg (range: 25 mg to 150 mg). Paliperidone palmitate is available in single-use prefilled syringes in dose strengths of paliperidone base of 50 mg per 0.5 mL, 75 mg per 0.75 mL, 100 mg per 1 mL, or 150 mg per 1.5

2011 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

642. Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study (Abstract)

Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study The authors conducted a randomized, placebo-controlled study of nicotine replacement therapy for the reduction of agitation and aggression in smokers with schizophrenia.Participants were 40 smokers 18-65 years of age admitted to a psychiatric emergency service with a diagnosis of schizophrenia confirmed by the Mini International Neuropsychiatric Interview (...) better than those with higher levels of dependence.The drug-placebo difference in this study was similar to that obtained in trials of parenteral antipsychotics in similar populations. This finding suggests that in patients with schizophrenia, smoking status should be included in the assessment of agitation and nicotine replacement included in the treatment of those who are smokers.

2011 EvidenceUpdates Controlled trial quality: uncertain

643. WITHDRAWN: Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. (Abstract)

WITHDRAWN: Cognitive behaviour therapy versus other psychosocial treatments for schizophrenia. Cognitive behavioural therapy (CBT) is now a recommended treatment for people with schizophrenia. This approach helps to link the person's feelings and patterns of thinking which underpin distress.To review the effects of CBT for people with schizophrenia when compared to other psychological therapies.We searched the Cochrane Schizophrenia Group Trials Register (March 2010) which is based on regular (...) searches of CINAHL, EMBASE, MEDLINE and PsycINFO. We inspected all references of the selected articles for further relevant trials, and, where appropriate, contacted authors.All relevant clinical randomised trials of cognitive behaviour therapy for people with schizophrenia-like illnesses.Studies were reliably selected and assessed for methodological quality. Two reviewers, working independently, extracted data. We analysed dichotomous data on an intention-to-treat basis and continuous data with 65

2011 Cochrane

644. Cognitive-behavioural therapy for persistent and recurrent psychosis in people with schizophrenia-spectrum disorder: cost-effectiveness analysis Full Text available with Trip Pro

Cognitive-behavioural therapy for persistent and recurrent psychosis in people with schizophrenia-spectrum disorder: cost-effectiveness analysis Evidence on cost-effectiveness is important to make well-informed decisions regarding care delivery.To determine the balance between costs and health outcomes of cognitive-behavioural therapy (CBT) compared with treatment as usual (TAU) in people with schizophrenia who have persistent and recurrent symptoms of psychosis.ISRCTN57292778.A total of 216

2011 EvidenceUpdates Controlled trial quality: uncertain

645. What support can community mental health nurses deliver to carers of people diagnosed with schizophrenia? Findings from a review of the literature (Abstract)

What support can community mental health nurses deliver to carers of people diagnosed with schizophrenia? Findings from a review of the literature The purpose of this review was to determine the nature of support that mental health nurses could deliver to carers of people diagnosed with schizophrenia. The aim was to identify approaches that could be delivered within community practice to reduce burden and increase knowledge, mental health and coping. QUESTIONS ADDRESSED: What effect did support (...) a quantitative assessment of carer outcomes were included. Findings were synthesised in narrative format and grouped by intervention type.Of the 68 emerging studies, 12 (18%) directly included nurses in delivering the intervention and 16 (24%) included nurses as part of a multidisciplinary team. There is fairly robust evidence that education improves carer knowledge of schizophrenia. There is, however, little evidence that it addresses more substantive areas such as burden, coping or mental health

2011 EvidenceUpdates

646. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine Full Text available with Trip Pro

Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine There is a need for a rapid-acting, non-injection, acute treatment for agitation.To evaluate inhaled loxapine for acute treatment of agitation in schizophrenia.This phase III, randomised, double-blind, placebo-controlled, parallel-group study (ClinicalTrials.gov number NCT00628589) enrolled 344 individuals who received one, two or three doses of inhaled (...) was evident 10 min after dose one with both 5 and 10 mg doses. Inhaled loxapine was well tolerated, and the most common adverse events were known effects of loxapine or minor oral effects common with inhaled medications.Inhaled loxapine provided a rapid, well-tolerated acute treatment for agitation in people with schizophrenia.

2011 EvidenceUpdates Controlled trial quality: predicted high

647. Effect of vitamins, fatty acids, minerals, and other dietary supplements on schizophrenic symptoms in people with schizophrenia

Effect of vitamins, fatty acids, minerals, and other dietary supplements on schizophrenic symptoms in people with schizophrenia Effect of vitamins, fatty acids, minerals, and other dietary supplements on schizophrenic symptoms in people with schizophrenia Effect of vitamins, fatty acids, minerals, and other dietary supplements on schizophrenic symptoms in people with schizophrenia Smedslund G, Berg RC Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Smedslund G, Berg RC. Effect of vitamins, fatty acids, minerals, and other dietary supplements on schizophrenic symptoms in people with schizophrenia. Oslo: Norwegian Knowledge Centre for the Health Services (NOKC). Report from NOKC no. 19 – 2011. 2011 Authors' conclusions We critically appraised randomized controlled trials about supplemental vitamins, fatty acids and other dietary

2011 Health Technology Assessment (HTA) Database.

648. Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years

Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years Overview | Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years | Guidance | NICE Aripiprazole for the treatment of schizophrenia in people aged 15 to 17 years Technology appraisal guidance [TA213] Published date: 26 January 2011 Share Guidance on aripiprazole for treating schizophrenia in young people aged 15 to 17. These recommendations are included in . Guidance development process

2011 National Institute for Health and Clinical Excellence - Technology Appraisals

649. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden

A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden Lindstrom E, Eberhard J, Fors BM, Hansen K, Sapin C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study compared the cost-effectiveness of sertindole with atypical antipsychotics (aripiprazole, olanzapine, risperidone and haloperidol) in adults with schizophrenia. The authors concluded that sertindole was a well-tolerated, effective and cost-effective treatment in Sweden. Given the information presented, uncertainty surrounding the assumptions and clinical estimates mean

2011 NHS Economic Evaluation Database.

650. Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study

Cost-effectiveness analysis of aripiprazole vs standard-of-care in the management of community-treated patients with schizophrenia: STAR study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 NHS Economic Evaluation Database.

651. [Antipsychotic polypharmacy in the treatment of schizophrenia]

[Antipsychotic polypharmacy in the treatment of schizophrenia] Antipsykotisk polyfarmaci i behandlingen af skizofreni [Antipsychotic polypharmacy in the treatment of schizophrenia] Antipsykotisk polyfarmaci i behandlingen af skizofreni [Antipsychotic polypharmacy in the treatment of schizophrenia] Baandrup L, Lublin H, Nordentoft M, Peacock L, Sorensen J, Andersen SE, Glenthoj B Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA (...) . No evaluation of the quality of this assessment has been made for the HTA database. Citation Baandrup L, Lublin H, Nordentoft M, Peacock L, Sorensen J, Andersen SE, Glenthoj B. Antipsykotisk polyfarmaci i behandlingen af skizofreni. [Antipsychotic polypharmacy in the treatment of schizophrenia] Copenhagen: Danish Centre for Evaluation and Health Technology Assessment (DACEHTA). Volume 11(1). 2011 Authors' objectives The aim of this health technology assessment is to explore how antipsychotic polypharmacy

2011 Health Technology Assessment (HTA) Database.

652. Regional variation in antipsychotic polypharmacy for schizophrenia Full Text available with Trip Pro

Regional variation in antipsychotic polypharmacy for schizophrenia Regional variation in antipsychotic polypharmacy for schizophrenia | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Regional variation in antipsychotic polypharmacy for schizophrenia Article Text Prevalence Regional variation in antipsychotic polypharmacy for schizophrenia Statistics from Altmetric.com Question Question Are there regional differences in the attitudes

2011 Evidence-Based Mental Health

653. Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline

Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline | Evidence-Based (...) OR managers of institutional accounts Username * Password * your user name or password? You are here Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics improved symptoms; quetiapine was superior to risperidone for people with major depression at baseline Article Text Therapeutics Effect of first-generation perphenazine and second-generation antipsychotics on depressive symptoms in schizophrenia: all antipsychotics

2011 Evidence-Based Mental Health

654. Inhaled loxapine reduces acute agitation in people with schizophrenia compared with placebo

Inhaled loxapine reduces acute agitation in people with schizophrenia compared with placebo Inhaled loxapine reduces acute agitation in people with schizophrenia compared with placebo | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Inhaled loxapine reduces acute agitation in people with schizophrenia compared with placebo Article Text Therapeutics Inhaled loxapine reduces acute agitation in people with schizophrenia compared with placebo

2011 Evidence-Based Mental Health

655. The effects of physical activity on psychological well-being for those with schizophrenia: a systematic review

The effects of physical activity on psychological well-being for those with schizophrenia: a systematic review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

656. Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder Full Text available with Trip Pro

Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder Aerosolised antipsychotic assuages agitation: inhaled loxapine for agitation associated with schizophrenia or bipolar disorder Citrome L CRD summary This review concluded that inhaled loxapine appeared efficacious and tolerable for the treatment (...) of agitation associated with schizophrenia or bipolar disorder. Given the considerable methodological limitations, particularly the limitations of the search strategy, lack of inclusion criteria and absence of consideration of bias, these conclusions should be interpreted with caution and may not be reliable. Authors' objectives To describe the efficacy and safety of inhaled loxapine for the treatment of agitation associated with schizophrenia or bipolar disorder. Searching Published trials were identified

2011 DARE.

657. Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis

Low dose vs standard dose of antipsychotics for relapse prevention in schizophrenia: meta-analysis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 DARE.

658. Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking

Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking | Evidence-Based Mental Health We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) in treatment of schizophrenia, but robust evidence is lacking Article Text Therapeutics Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking Statistics from Altmetric.com Question Question How does clozapine compare with other atypical antipsychotics in the treatment of schizophrenia and schizophrenia-like psychoses? Outcomes Mental states assessed by a range of scales (Brief Psychiatric Rating Scale, Positive

2011 Evidence-Based Mental Health

659. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder

Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder Kasteng F, Eriksson J, Sennfalt K, Lindgren P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to assess the cost-effectiveness of aripiprazole versus olanzapine for schizophrenia or bipolar disorder, focusing on the risk of developing treatment-related metabolic syndrome, leading to type 2 diabetes or coronary heart disease. The lower risk of metabolic syndrome

2011 NHS Economic Evaluation Database.

660. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. Full Text available with Trip Pro

Long-acting risperidone and oral antipsychotics in unstable schizophrenia. Long-acting injectable risperidone, a second-generation antipsychotic agent, may improve adherence to treatment and outcomes in schizophrenia, but it has not been tested in a long-term randomized trial involving patients with unstable disease.We randomly assigned patients in the Veterans Affairs (VA) system who had schizophrenia or schizoaffective disorder and who had been hospitalized within the previous 2 years or were (...) with long-acting injectable risperidone as compared with control treatments. Patients who received long-acting injectable risperidone reported more adverse events at the injection site and more extrapyramidal symptoms.Long-acting injectable risperidone was not superior to a psychiatrist's choice of oral treatment in patients with schizophrenia and schizoaffective disorder who were hospitalized or at high risk for hospitalization, and it was associated with more local injection-site and extrapyramidal

2011 NEJM Controlled trial quality: predicted high